The role of EPH receptors in cancer-related epithelial-mesenchymal transition  

作　　者：Rui-Xin Li Zi-Hua Chen Zhi-Kang Chen 

机构地区：[1]Department of Gastrointestinal Surgery,Xiangya Hospital,Central South University

出　　处：《Chinese Journal of Cancer》2014年第5期231-240,共10页

摘　　要：Erythropoietin-producing hepatoma(EPH) receptors are considered the largest family of receptor tyrosine kinases and play key roles in physiological and pathologic processes in development and disease.EPH receptors are often overexpressed in human malignancies and are associated with poor prognosis.However,the functions of EPH receptors in epithelial-mesenchymal transition(EMT) remain largely unknown.This review depicts the relationship between EPH receptors and the EMT marker E-cadherin as well as the crosstalk between EPH receptors and the signaling pathways involved EMT.Further discussion is focused on the clinical significance of EPH receptors as candidates for targeting in cancer therapeutics.Finally,we summarize how targeted inhibition of both EPH receptors and EMT-related signaling pathways represents a novel strategy for cancer treatment.Erythropoietin-producing hepatoma （EPH） receptors are considered the largest family of receptor tyrosine kinases and play key roles in physiological and pathologic processes in development and disease. EPH receptors are often overexpressed in human malignancies and are associated with poor prognosis. However, the functions of EPH receptors in epithelial-mesenchymal transition （EMT） remain largely unknown. This review depicts the relationship between EPH receptors and the EMT marker E-cadherin as well as the crosstaik between EPH receptors and the signaling pathways involved EMT. Further discussion is focused on the clinical significance of EPH receptors as candidates for targeting in cancer therapeutics. Finally, we summarize how targeted inhibition of both EPH receptors and EMT-related signaling pathways represents a novel strategy for cancer treatment.

关 键 词：受体酪氨酸激酶 恶性肿瘤 上皮 转化 间质 促红细胞生成素 信号通路 癌症治疗 

分 类 号：R730.5[医药卫生—肿瘤]